Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
asset turnover							0.00 -	0.17 6,357.85%	0.21 21.26%
cash conversion cycle							-70.60K -	3.94K 105.58%	4.80K 21.86%
cash per share	0.15 -	3.78 2,416.17%	11.60 206.47%	4.43 61.75%	7.44 67.72%	9.34 25.51%	10.46 12.03%	9.14 12.56%	10.88 18.99%
company equity multiplier	-0.24 -	-1.13 375.70%	1.09 196.18%	1.09 0.08%	1.12 3.00%	1.08 3.63%	1.38 27.58%	1.74 26.46%	4.78 174.86%
days of inventory outstanding							9.71K -	7.39K 23.87%	6.41K 13.34%
days of payables outstanding							80.76K -	3.51K 95.66%	1.66K 52.61%
days of sales outstanding							456.60 -	51.59 88.70%	53.98 4.62%
dividend yield
ebit per revenue							-133.44 -	-1.96 98.53%	-1.48 24.79%
ebt per ebit	1.16 -	1.01 12.29%	1.00 1.49%	0.99 0.72%	0.98 1.08%	0.95 2.87%	0.95 0.51%	1.02 7.34%	1.05 3.33%
effective tax rate									-0.00 -
enterprise value multiple	-53.26 -	-26.87 49.55%	-5.84 78.27%	-4.77 18.23%	-12.72 166.40%	-10.76 15.41%	-17.17 59.58%	-10.20 40.57%	-6.52 36.07%
fixed asset turnover							0.03 -	1.40 5,195.28%	2.35 68.06%
free cash flow per share	-0.72 -	-1.49 107.06%	-2.49 67.58%	-2.08 16.45%	-2.27 9.18%	-2.74 20.68%	-3.39 23.79%	-3.60 6.02%	-4.13 14.89%
gross profit margin							0.98 -	0.98 0.69%	0.98 0.10%
interest coverage								-24.79 -	-18.60 24.97%
inventory turnover							0.04 -	0.05 31.36%	0.06 15.39%
long term debt to capitalization							0.11 -	0.26 133.56%	0.77 191.96%
net income per ebt	1 -	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1.00 0.16%
net profit margin							-126.55 -	-2.00 98.42%	-1.56 22.17%
operating cash flow per share	-0.67 -	-1.46 116.82%	-2.41 64.97%	-2.04 15.45%	-2.20 7.77%	-2.65 20.42%	-3.33 25.96%	-3.45 3.62%	-4.08 18.15%
operating cycle							10.17K -	7.44K 26.78%	6.46K 13.21%
operating profit margin							-133.44 -	-1.96 98.53%	-1.48 24.79%
payables turnover							0.00 -	0.10 2,203.41%	0.22 111.00%
pretax profit margin							-126.55 -	-2.00 98.42%	-1.55 22.29%
price fair value	-36.18 -	-12.03 66.76%	2.94 124.45%	2.58 12.42%	5.22 102.83%	3.67 29.83%	8.01 118.54%	6.38 20.32%	9.38 46.91%
receivables turnover							0.80 -	7.07 784.98%	6.76 4.42%
return on assets	-2.94 -	-0.37 87.29%	-0.30 18.84%	-0.41 34.54%	-0.33 19.49%	-0.28 14.03%	-0.34 18.81%	-0.34 2.04%	-0.32 5.62%
return on capital employed	-6.50 -	-0.39 94.07%	-0.33 15.44%	-0.44 36.49%	-0.36 18.88%	-0.31 13.26%	-0.39 24.02%	-0.38 2.87%	-0.34 10.36%
return on equity	0.70 -	0.42 39.52%	-0.33 178.06%	-0.44 34.43%	-0.37 17.07%	-0.30 17.15%	-0.46 51.58%	-0.59 29.04%	-1.54 159.42%
total debt to capitalization							0.12 -	0.27 133.86%	0.77 185.76%

NASDAQ:GBT

Global Blood Therapeutics, Inc.

Last Close

68.48

04/10 20:00

Volume Today

3.28M

Avg: -

PE Ratio

−27.41

PFCF: -